Literature DB >> 16698423

Rotavirus-specific CD5+ B cells in young children exhibit a distinct antibody repertoire compared with CD5- B cells.

Jörn-Hendrik Weitkamp1, Bonnie J Lafleur, James E Crowe.   

Abstract

Antiviral antibody responses in infants are limited in quality. One reason for this finding could be that the majority of B cells in infants are CD5+ cells, a subset of B cells that is thought to contain cells expressing polyreactive, low-affinity B cell receptors. We analyzed the rotavirus (RV)-specific antibody heavy chain variable region (VH) repertoire in CD5+ and CD5- B cells of four RV-infected children between 10 and 19 months of age. We found that the RV-specific B cell repertoire in CD5+ cells was VH3 family biased, in contrast to the VH1/VH4 dominance seen in CD5- B cells. The immunodominant RV-specific gene segment in CD5- B cells was VH1-46, which is the dominant segment used in RV-specific peripheral blood B cells from infants and adults. In contrast, the immunodominant gene segment was VH3-23 in RV-specific CD5+ B cells, which is the dominant gene segment in randomly selected B cells. Both RV-specific CD5+ and RV-specific CD5- B cells from all children studied demonstrated very low frequencies of somatic mutations. In conclusion, CD5+ B cells in infants responding to RV use an antibody gene repertoire that differs from the virus-specific repertoire of CD5- B cells, and both CD5+ and CD5- RV-specific B cells exhibit a low frequency of somatic mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698423     DOI: 10.1016/j.humimm.2006.02.024

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

Review 2.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Differential accessibility of a rotavirus VP6 epitope in trimers comprising type I, II, or III channels as revealed by binding of a human rotavirus VP6-specific antibody.

Authors:  Mohammed S Aiyegbo; Ilyas M Eli; Benjamin W Spiller; Dewight R Williams; Robert Kim; David E Lee; Tong Liu; Sheng Li; Phoebe L Stewart; James E Crowe
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

4.  Emerging studies of human HIV-specific antibody repertoires.

Authors:  Mark D Hicar; Spyros A Kalams; Paul W Spearman; James E Crowe
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

Review 5.  Safety and efficacy of neonatal vaccination.

Authors:  Alicia Demirjian; Ofer Levy
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 6.  Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.

Authors:  E Clarke; U Desselberger
Journal:  Mucosal Immunol       Date:  2014-12-03       Impact factor: 7.313

7.  The human intestinal IgA response; burning questions.

Authors:  Jo Spencer; Linda S Klavinskis; Louise D Fraser
Journal:  Front Immunol       Date:  2012-05-11       Impact factor: 7.561

8.  Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore.

Authors:  Mohammed S Aiyegbo; Gopal Sapparapu; Benjamin W Spiller; Ilyas M Eli; Dewight R Williams; Robert Kim; David E Lee; Tong Liu; Sheng Li; Virgil L Woods; David P Nannemann; Jens Meiler; Phoebe L Stewart; James E Crowe
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

Review 9.  The gastrointestinal frontier: IgA and viruses.

Authors:  Sarah E Blutt; Margaret E Conner
Journal:  Front Immunol       Date:  2013-11-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.